**Table 2:** **Relative incidence in at-risk period versus control period of all outcomes (modelled independently) for all vaccines, adjusted for season**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Zoster vaccine** | | | **Pneumococcal vaccine** | | | **Influenza vaccine** | | |
|  | **At-risk n**  **(PD)** | **Control n (PD)** | **RI (95% CI)** | **At-risk n (PD)** | **Control n (person days)** | **RI (95% CI)** | **At-risk n (RD)** | **Control n (person days)** | **RI (95% CI)** |
| **Injection site reaction** | 37  (833) | 104  (96 876) | 77.39 (48.06, 124.62) | 30  (378) | 138  (102,318) | 65.02 (31.65, 133.58) | 29  (1,071) | 102  (84,934) | 6.62 (3.42, 12.80) |
| **Burn** | 72  (23,798) | 1,282  (511,166) | 1.23 (0.97, 1.57) | 8  (5,259) | 1,455  (564,087) | 0.55 (0.27, 1.13) | 145  (57,946) | 1,036  (407,960) | 0.93 (0.76, 1.14) |
| **Myocardial infarction** | 12  (8,327) | 436  (221,244) | 0.74 (0.41, 1.33) | 2  (2,729) | 469  (237,376) | 0.39 (0.09,1.59) | 47  (23,226) | 324  (176,808) | 1.17 (0.82, 1.66) |
| **Stroke** | 50  (35,113) | 1,984  (793,445) | 0.58 (0.44, 0.78) | 15  (9,081) | 2,132  (868,410) | 0.72 (0.42, 1.21) | 197  (88,397) | 1,500  (633,321) | 1.06 (0.89, 1.26) |
| **Any rash** | 422  (228,311) | 10,381  (4,990,170) | 0.97 (0.88, 1.08) | 115  (52,961) | 11,959  (5,497,005) | 1.01 (0.84, 1.23) | 1,124  (564,634) | 8,645  (3,982,480) | 1.06 (0.98, 1.14) |
| **Rash with antiviral** | 61  (33,800) | 1,570  (856,854) | 0. 83 (0.62, 1.10) | 22  (10,571) | 1,931  (1,099,845) | 1.23 (0.77, 1.95) | 104  (73,998) | 917  (455,454) | 0.78 (0.62, 0.97) |
| **Clinical attendance** | 79,352  (3,726,764) | 1,799,288  (79,138,828) | 0.94 (0.94, 0.95) | 19,616  (848,864) | 2,032,393 (87,483,370) | 1.06 (1.04, 1.07) | 200,785  (8,840,389) | 1,368,928  (63,862,675) | 1.03 (1.02, 1.03) |

CI: Confidence interval, n: number of events, PD: person days, RI: Relative incidence.